TB-500

01

Investigation

What is being claimed?

Systemic healing for tendon, ligament, muscle, sometimes heart. The other half of the BPC-157 stack. “Thymosin beta-4” with company trials attached to the name. Safer or more whole-body than local injection peptides.

People often assume TB-500 inherits the same evidence they think BPC-157 has. The harder problem is what object is in the vial.

Identity comes before efficacy. If you don't know which molecule you're discussing, you can't borrow its evidence.

02

Investigation

What is actually known?

Mechanism

Thymosin beta-4 biology is real in cell and animal repair models. TB-500 marketing usually points at a fragment of that story, not the full-length peptide some developers studied.

Human evidence split

Full-length thymosin beta-4: Phase 2–range human work exists in specific medical contexts (ophthalmic / wound programs in company history). Evidence about full-length Tβ4 does not automatically validate gray-market TB-500 fragment vials.

TB-500 fragment: Injury-recovery claims that dominate forums still lack a published human efficacy RCT package for the fragment under those endpoints. FDA 2026 compounding briefing materials emphasize insufficient human effectiveness data for the fragment under proposed injectable wellness uses.

Registered trial chatter: Secondary sources cite a 2026 Phase 1/2 TB-500 / Tβ4 17–23 fragment study in stable ASCVD (often under NCT07487363). The ClinicalTrials.gov page for that ID currently describes itself as a fictional / example record. Do not treat that NCT as settled evidence of an active human program. Even a real CV safety/biomarker trial would not equal proof for hamstring stack protocols.

Compared to BPC-157

Shared recovery-peptide culture. Different mechanism emphasis and a fragment-vs-full-length identity gap. No high-quality published RCT of the BPC-157 + TB-500 stack for return-to-sport or recomposition was identified.

Regulatory / product

Not FDA-approved for the uses patients usually mean. Compounding contested; 2026 PCAC activity in FDA staff materials (advisory; verify current status). WADA-prohibited framing matters for tested athletes. Purity and label accuracy are clinical concerns.

03

Investigation

What remains uncertain?

• Whether fragment pharmacology matches full-length enough to borrow trial credibility
• Whether new trials will answer injury claims or only narrow medical questions
• Long-term safety of repeated fragment injection outside trials
• How much stack results are peptide vs rehab, sleep, nutrition, and concurrent meds

04

Investigation

Why should an RD care?

Identity literacy. TB-500, thymosin beta-4, and full-length Tβ4 are related but not identical. When a patient cites trials, ask which molecule and which indication.

Comparison literacy. Shared stack culture with BPC-157 ≠ shared evidence map.

Product quality. Compounded, clinic, or research-chem sourcing. Identity problems get worse when labels lie.

Recovery still lives in nutrition and rehab. Protein, calories, sleep, load management, and appropriate medical care do not become optional because a stack was added.

Sport ban literacy. Tested athletes need a straight answer.

Usable line: “TB-500 is usually a fragment related to thymosin beta-4, not the same thing as full-length thymosin beta-4 studied in some company trials. Preclinical repair biology is interesting. Human proof for the fragment under tendon-and-ligament recovery claims is still thin. Stacking with BPC-157 is common; it isn’t backed by a solid published stack trial.”